

Caterina Ricci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2782107/publications.pdf>

Version: 2024-02-01

27
papers

1,330
citations

567281

15
h-index

526287

27
g-index

27
all docs

27
docs citations

27
times ranked

2106
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP Inhibitors Resistance: Mechanisms and Perspectives. <i>Cancers</i> , 2022, 14, 1420.	3.7	22
2	Neoadjuvant chemotherapy followed by conization in stage IB2-IIA1 cervical cancer larger than 2 cm: a Pilot study. <i>Fertility and Sterility</i> , 2021, 115, 148-156.	1.0	17
3	HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study. <i>Vaccines</i> , 2021, 9, 643.	4.4	4
4	Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives. <i>Biology</i> , 2021, 10, 845.	2.8	6
5	Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. <i>Seminars in Cancer Biology</i> , 2021, 77, 144-166.	9.6	50
6	Are We Facing a New Colposcopic Practice in the HPV Vaccination Era? Opportunities, Challenges, and New Perspectives. <i>Vaccines</i> , 2021, 9, 1081.	4.4	8
7	Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NITCHE trial (MITO 33). <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1369-1373.	2.5	12
8	Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103542.	4.4	3
9	Final results from GCG/ENGOT/AGO-EOVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. <i>International Journal of Cancer</i> , 2020, 146, 439-448.	5.1	40
10	Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. <i>Gynecologic Oncology</i> , 2020, 156, 523-529.	1.4	31
11	Cancer and Mediterranean Diet: A Review. <i>Nutrients</i> , 2019, 11, 2059.	4.1	255
12	Effect of age and cone dimensions on cervical regeneration: an Italian multicentric prospective observational study. <i>BMJ Open</i> , 2018, 8, e020675.	1.9	12
13	Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome. <i>Gynecologic Oncology</i> , 2018, 150, 398-405.	1.4	16
14	Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1141-1148.	2.5	3
15	A randomized phase II study assessing an optimized schedule of oregovomab (O) anti-CA125 vaccination with carboplatin paclitaxel (CP) relative to CP alone in front-line treatment of optimally cytoreduced stage III/IV ovarian cancer (EOC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5536-5536.	1.6	2
16	Locally Advanced Cervical Cancer in Pregnancy: Overcoming the Challenge. A Case Series and Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1490-1496.	2.5	16
17	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 561-568.	10.7	141
18	Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. <i>OncoTargets and Therapy</i> , 2014, 7, 1273.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Long-term efficacy and safety of human papillomavirus vaccination. <i>International Journal of Women's Health</i> , 2014, 6, 999.	2.6	80
20	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	10.7	327
21	HPV vaccine cross-protection: Highlights on additional clinical benefit. <i>Gynecologic Oncology</i> , 2013, 130, 642-651.	1.4	61
22	Bowel Endometriosis with Hemoperitoneum Complicating Pregnancy. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2013, 5, 166-169.	0.5	4
23	Time Trade-Off Procedure for Measuring Health Utilities Loss With Human Papillomavirus-Induced Diseases: A Multicenter, Retrospective, Observational Pilot Study in Italy. <i>Clinical Therapeutics</i> , 2011, 33, 1084-1095.e4.	2.5	13
24	Clinical Performance of Human Papillomavirus E6 and E7 mRNA Testing for High-Grade Lesions of the Cervix. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3895-3901.	3.9	63
25	Treatment of cervical cancer in Italy: Strategies and their impact on the women. <i>Vaccine</i> , 2009, 27, A39-A45.	3.8	13
26	Quality of life and psychological distress in locally advanced cervical cancer patients administered pre-operative chemoradiotherapy. <i>Gynecologic Oncology</i> , 2008, 111, 144-150.	1.4	62
27	Vascular Involvement in Inflammatory Bowel Disease: Pathogenesis and Clinical Aspects. <i>Digestive Diseases</i> , 2008, 26, 149-155.	1.9	60